Cost-effectiveness of augmenting current perinatal hepatitis B prevention program with maternal antiviral therapy

Hepatology. 2017 Mar;65(3):1074-1075. doi: 10.1002/hep.28904. Epub 2016 Nov 29.

Authors

Gang Qin^{1

2}, Xun Zhuang²

Affiliations

¹ Center for liver Diseases, Nantong Third People's Hospital, Nantong University, Nantong, China.
² Department of Epidemiology and Biostatistics, School of Public Health, Nantong University, Nantong, China.

PMID: 27785834
DOI: 10.1002/hep.28904

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antiviral Agents
Cost-Benefit Analysis*
Female
Hepatitis B*
Hepatitis B, Chronic
Humans
Infectious Disease Transmission, Vertical / prevention & control
Pregnancy

Substances

Antiviral Agents